Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- InnoCare Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Placebo + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone is the control arm regimen used in a Phase III clinical trial (NCT04914117) sponsored by InnoCare Pharma. This combination pairs a placebo tablet with the standard-of-care R-CHOP chemoimmunotherapy for the treatment of treatment-naïve patients with the MCD (MYD88/CD79B) genetic subtype of diffuse large B-cell lymphoma (DLBCL). R-CHOP consists of rituximab, a CD20-directed monoclonal antibody; cyclophosphamide, an alkylating agent; doxorubicin, an anthracycline topoisomerase II inhibitor; vincristine, a microtubule inhibitor; and prednisone, a corticosteroid. The study evaluates whether the addition of the BTK inhibitor orelabrutinib to R-CHOP provides superior efficacy over this placebo-controlled standard regimen.
- Other names
- Placebo + R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on placebo + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.